Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: YM150 for VTE Prevention in Knee Arthroplasty
NCT00595426Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- May 2008
- Primary completion
- May 2009
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of darexaban in venous thromboembolism (VTE) (5 arms), sponsored by Astellas Pharma. Primary endpoints: Total Venous Thromboembolism at 6 weeks and Major Bleeding at 6 weeks. Started May 2008; status: completed.
02
Drugs
darexaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00595426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595426.